TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/30/2023
Back to search
Official data from USPTO
9METERS BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
9METERS BIOPHARMA
ST13
US500000088983913Class
42
Filing
88983913
Registration
6725571
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
07/08/2023
Trademark type
Word
Nice classes
42
Filing date
08/09/2019
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
07/08/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2020-07-00
First use in commerce
2020-07-00
Drawing code
4
Owner type
03
Owner location
Raleigh, NC
Examiner
EISNACH, MICHAEL
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
9 METERS BIOPHARMA
9 METERS BIOPHARMA
RDD Pharma, Inc.
Representatives
Devon E. White WYRICK ROBBINS YATES & PONTON LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development services; Medical and scientific research information in the field of novel pharmaceutical discovery and development; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Medical and scientific researchconducting clinical trials for others of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of New Therapeutic Entities (NTEs) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither New Chemical Entities (NCEs) nor generics and New Chemical Entities (NCEs) and Biologic License Application (BLAs) as novel pharmaceutical treatments; Research and development in the field of novel pharmaceutical treatments and clinical trials; Providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; Clinical trials services for others
Publications
History of USPTO decisions and trademark events.
46 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/30/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/30/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/30/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/30/2023
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
04/26/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/08/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/07/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/04/2022
DPCC
DIVISIONAL PROCESSING COMPLETE
03/04/2022
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/28/2022
IUAF
USE AMENDMENT FILED
02/11/2022
DRRR
DIVISIONAL REQUEST RECEIVED
02/11/2022
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
02/11/2022
EISU
TEAS STATEMENT OF USE RECEIVED
02/11/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
12/22/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/20/2021
EX3G
SOU EXTENSION 3 GRANTED
08/18/2021
EXT3
SOU EXTENSION 3 FILED
08/18/2021
EEXT
SOU TEAS EXTENSION RECEIVED
08/18/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/12/2020
EX2G
SOU EXTENSION 2 GRANTED
12/10/2020
EXT2
SOU EXTENSION 2 FILED
12/10/2020
EEXT
SOU TEAS EXTENSION RECEIVED
12/10/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/15/2020
EX1G
SOU EXTENSION 1 GRANTED
08/13/2020
EXT1
SOU EXTENSION 1 FILED
08/13/2020
EEXT
SOU TEAS EXTENSION RECEIVED
08/13/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/18/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/24/2019
PUBO
PUBLISHED FOR OPPOSITION
12/24/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/04/2019
ALIE
ASSIGNED TO LIE
11/18/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/14/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
11/14/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/14/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
11/14/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/14/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/14/2019
GNRT
NON-FINAL ACTION E-MAILED
11/14/2019
CNRT
NON-FINAL ACTION WRITTEN
11/14/2019
DOCK
ASSIGNED TO EXAMINER
11/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/26/2019
NWAP
NEW APPLICATION ENTERED
08/13/2019
Continuous trademark protection
Get notified about every new filing that threatens 9METERS BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.